CytomX Therapeutics, Inc. (CTMX) financial statements (2021 and earlier)

Company profile

Business Address 151 OYSTER POINT BLVD.
SOUTH SAN FRANCISCO, CA 94080
State of Incorp.
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:256296436374182187
Cash and cash equivalents19218824817810560
Short-term investments12410818919777127
Other undisclosed cash, cash equivalents, and short-term investments(60)   (0)(0)
Receivables1001021
Other undisclosed current assets6779442
Total current assets:324303445389188190
Noncurrent Assets
Operating lease, right-of-use asset2225
Property, plant and equipment777443
Intangible assets, net (including goodwill)222333
Goodwill111111
Intangible assets, net (excluding goodwill)111222
Restricted cash and investments111111
Other noncurrent assets221130
Total noncurrent assets:3538129117
TOTAL ASSETS:359341457398199197
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities263445211510
Accounts payable345475
Accrued liabilities2330271695
Taxes payable  13   
Deferred revenue7551
Deferred revenue and credits41206
Contract with customer, liability53
Total current liabilities:1018698613616
Noncurrent Liabilities
Long-term debt and lease obligation2225    
Operating lease, liability2225
Liabilities, other than long-term debt1861802282678555
Deferred revenue and credits2658455
Deferred revenue186179
Contract with customer, liability225
Deferred tax liabilities, net  11
Other liabilities 13210
Total noncurrent liabilities:2082052282678555
Total liabilities:30929032632812171
Stockholders' equity
Stockholders' equity attributable to parent, including:50511317078126
Common stock000000
Additional paid in capital500468446289255244
Accumulated other comprehensive income (loss)(0)0(0)(0)(0)(0)
Accumulated deficit(450)(417)(315)(219)(176)(117)
Other undisclosed stockholders' equity attributable to parent     (0)
Total stockholders' equity:50511317078126
TOTAL LIABILITIES AND EQUITY:359341457398199197

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenue, net7215 
Gross profit:100576072158
Operating expenses(149)(168)(137)(118)(75)(41)
Operating loss:(49)(111)(78)(46)(60)(33)
Nonoperating income (expense)28832(0)
Investment income, nonoperating288321
Other nonoperating expense(0)(0)(0)(0)(0)(2)
Interest and debt expense    (2)(2)
Loss from continuing operations before income taxes:(47)(103)(70)(44)(59)(35)
Income tax expense (benefit)140(14)10(0)
Net loss attributable to parent:(33)(102)(85)(43)(59)(35)
Preferred stock dividends and other adjustments     (7)
Net loss available to common stockholders, diluted:(33)(102)(85)(43)(59)(42)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(33)(102)(85)(43)(59)(35)
Other comprehensive income (loss)  0(0)0(0)
Comprehensive loss:(33)(102)(85)(43)(59)(35)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(0)0    
Comprehensive loss, net of tax, attributable to parent:(33)(102)(85)(43)(59)(35)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: